Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 59Squamous Cell Carcinoma of Head and Neck 32Carcinoma, Non-Small-Cell Lung 29Neoplasms 26Head and Neck Neoplasms 26Colonic Neoplasms 20Neoplasm Metastasis 17Rectal Neoplasms 12Breast Neoplasms 11Lung Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Squamous Cell 6Tongue Neoplasms 5Salivary Gland Neoplasms 5Melanoma 5Stomach Neoplasms 4Solid Tumors 4Ovarian Neoplasms 4Carcinoma, Renal Cell 4Advanced Solid Tumor 4Triple Negative Breast Neoplasms 3Sarcoma 3Kidney Neoplasms 3Endometrial Neoplasms 3Advanced Cancers 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Recurrence 2Pharyngeal Neoplasms 2Neoplasms by Site 2

Interventions

Vorinostat 2nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Hydroxychloroquine 1Dasatinib 1DOXO-EMCH 1Cetuximab 1BN 80927 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Malignant Solid Tumour × Cetuximab × Clear all
NCT00388427 2015-05-28

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

University of Pittsburgh

Phase 1 Completed
31 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡